Article
A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma.
Oncotarget - 2 Feb 2016
Hu Zhongqian, Wang Xinyi, Fang Haoshu, Liu Yakun, Chen Danlei, Zhang Qian, Liu Xia, Wei Daoyan, Qu Chengkui, Wang Siying
Abstract excerpt
BACKGROUND: Evidence suggests that Src homologous protein phosphotyrosyl phosphatase 2 (SHP2) mutations promote cancer development in several solid tumours. In this study, we focused on the in vivo and in vitro effects of an SHP2 mutation on the breast cancer phenotype to determine whether this mutation is correlated with a malignant phenotype. METHODS: Mutant PTPN11 cDNA (D61G) was transduced into MDA-MB231 and...
Topics
- Animals
- Apoptosis
- Blotting, Western
- Breast Neoplasms
- Cell Adhesion
- Cell Movement
- Cell Proliferation
- Enzyme Activation
- Female
- Humans
- Immunoenzyme Techniques